autolus
therapeutics
reports
third
quarter
financial
results
operational
progress
nasdaq
autl
london
globe
newswire
autolus
therapeutics
plc
nasdaq
autl
biopharmaceutical
company
developing
programmed
cell
therapies
today
announced
operational
financial
results
third
quarter
ended
september
made
steady
progress
third
quarter
continued
enroll
alexander
outpatient
cohort
well
program
planned
fourth
quarter
winter
months
continue
monitor
situation
adjust
trial
conduct
accordingly
said
christian
itin
chairman
chief
executive
officer
autolus
esmo
presented
data
recommended
phase
dose
cohort
alexander
trial
showing
high
level
complete
remissions
well
tolerated
safety
profile
look
forward
presenting
update
study
ash
meeting
december
along
data
allcar
study
adult
pipeline
updates
data
presented
european
society
medical
oncology
esmo
virtual
congress
recommended
phase
dose
cohort
alexander
trial
dual
targeting
car
product
candidate
relapsed
refractory
diffuse
large
b
cell
lymphoma
dlbcl
data
presented
oral
presentations
american
society
hematology
ash
december
adult
acute
lymphoblastic
leukemia
longer
term
follow
dlbcl
updated
data
longer
term
follow
alexander
study
adult
acute
lymphoblastic
leukemia
longer
term
follow
dlbcl
updated
data
longer
term
follow
alexander
study
plans
progress
solid
tumor
programs
positive
tumors
prostate
cancer
clinic
key
upcoming
clinical
milestones
clinical
updates
adult
allcar
study
ash
december
clinical
update
dlbcl
alexander
study
ash
initiation
phase
study
pediatric
phase
interim
data
cell
lymphoma
initiation
phase
studies
solid
tumors
first
exploratory
allogeneic
program
expected
enter
clinic
financial
results
third
quarter
cash
equivalents
september
totaled
million
compared
million
june
net
total
operating
expenses
three
months
ended
september
million
net
grant
income
million
license
revenue
million
compared
net
operating
expenses
million
net
grant
income
million
period
research
development
expenses
increased
million
three
months
ended
september
million
three
months
ended
september
cash
costs
exclude
depreciation
amortization
well
compensation
increased
million
million
increase
research
development
cash
costs
million
consisted
primarily
increase
compensation
employment
related
costs
net
lower
travel
costs
result
ongoing
pandemic
million
due
increase
employee
headcount
support
advancement
product
candidates
clinical
development
ii
increase
million
project
expenses
consequence
advancement
clinical
portfolio
includes
research
process
development
manufacturing
activities
necessary
prepare
activate
monitor
clinical
trial
programs
iii
increase
million
facilities
costs
related
commencement
lease
manufacturing
facility
continued
scaling
manufacturing
operations
iv
increase
million
infrastructure
support
information
systems
related
conduct
clinical
trials
v
increase
million
related
cell
logistics
vi
increase
million
legal
professional
fees
offset
decreases
materials
purchases
million
costs
decreased
million
three
months
ended
september
million
three
months
ended
september
decrease
primarily
related
compensation
expense
included
research
development
expenses
decreased
million
result
lower
fair
value
stock
options
recognized
period
offset
million
increase
depreciation
general
administrative
expenses
increased
million
three
months
ended
september
million
three
months
ended
september
cash
costs
exclude
depreciation
expense
well
expense
compensation
increased
million
million
increase
million
commercial
activities
ii
increase
million
patent
legal
fees
audit
fees
costs
incurred
result
public
company
iii
increase
million
compensation
employment
related
costs
due
increase
headcount
net
lower
travel
costs
costs
decreased
million
three
months
ended
september
million
three
months
ended
september
decrease
attributed
compensation
expense
result
lower
fair
value
stock
options
recognized
period
interest
income
decreased
million
three
months
ended
september
due
lower
interest
rates
cash
held
deposit
expense
income
decreased
million
three
months
ended
september
income
million
three
months
ended
september
expense
million
primarily
due
decrease
million
regard
weakening
dollar
exchange
rate
relative
pound
sterling
three
months
ended
september
compared
three
months
ended
september
offset
lease
termination
gains
million
income
tax
benefit
increased
million
three
months
ended
september
million
three
months
ended
september
due
increased
research
development
credits
research
development
credits
grew
faster
rate
net
loss
income
tax
led
higher
effective
tax
rate
research
development
credits
obtained
maximum
rate
qualifying
research
development
expenses
increase
net
credit
primarily
attributable
increase
eligible
research
development
expenses
net
loss
attributable
ordinary
shareholders
million
three
months
ended
september
compared
million
period
basic
diluted
net
loss
per
ordinary
share
three
months
ended
september
totaled
compared
basic
diluted
net
loss
per
ordinary
share
three
months
ended
september
company
anticipates
cash
hand
sufficient
fund
operations
conference
call
presentation
information
management
host
conference
call
webcast
et
pm
gmt
discuss
company
financial
results
provide
general
business
update
listen
webcast
view
accompanying
slide
presentation
please
go
https
events
call
may
also
accessed
dialing
canada
callers
international
callers
please
reference
conference
id
conference
call
replay
available
one
week
access
replay
please
dial
canada
callers
international
callers
please
reference
conference
id
autolus
therapeutics
plc
autolus
biopharmaceutical
company
developing
programmed
cell
therapies
treatment
cancer
using
broad
suite
proprietary
modular
cell
programming
technologies
company
engineering
precisely
targeted
controlled
highly
active
cell
therapies
designed
better
recognize
cancer
cells
break
defense
mechanisms
eliminate
cells
autolus
pipeline
product
candidates
development
treatment
hematological
malignancies
solid
tumors
information
please
visit
statements
press
release
contains
statements
within
meaning
safe
harbor
provisions
private
securities
litigation
reform
act
statements
statements
historical
facts
cases
identified
terms
may
could
expects
plans
anticipates
believes
statements
include
limited
statements
regarding
efficacy
safety
therapeutic
potential
future
clinical
development
including
progress
expectations
reporting
data
conduct
timing
statements
based
management
current
views
assumptions
involve
risks
uncertainties
could
cause
actual
results
performance
events
differ
materially
expressed
implied
statements
risks
uncertainties
include
limited
risks
autolus
preclinical
clinical
programs
advance
result
approved
products
timely
cost
effective
basis
results
early
clinical
trials
always
predictive
future
results
cost
timing
results
clinical
trials
many
product
candidates
become
approved
drugs
timely
cost
effective
basis
ability
enroll
patients
clinical
trials
possible
safety
efficacy
concerns
impact
ongoing
pandemic
autolus
business
discussion
risks
uncertainties
important
factors
could
cause
autolus
actual
results
differ
contained
statements
see
section
titled
risk
factors
autolus
annual
report
form
filed
securities
exchange
commission
march
amended
well
discussions
potential
risks
uncertainties
important
factors
autolus
subsequent
filings
securities
exchange
commission
information
press
release
date
release
company
undertakes
obligation
publicly
update
statement
whether
result
new
information
future
events
otherwise
except
required
law
contact
lucinda
crabtree
phd
vice
president
investor
relations
corporate
communications
julia
wilson
susan
noonan
noonan
communications
susan
autolus
therapeutics
plc
condensed
consolidated
statements
operations
comprehensive
loss
unaudited
thousands
except
share
per
share
amounts
three
months
ended
september
nine
months
ended
september
grant
income
license
revenue
operating
expenses
research
development
general
administrative
total
operating
expenses
net
income
expense
interest
income
expense
income
total
expense
income
net
net
loss
income
tax
income
tax
benefit
net
loss
attributable
ordinary
shareholders
comprehensive
loss
income
foreign
currency
exchange
translation
adjustment
total
comprehensive
loss
basic
diluted
net
loss
per
ordinary
share
basic
diluted
ordinary
shares
condensed
consolidated
balance
sheets
unaudited
thousands
except
share
per
share
amounts
september
december
assets
current
assets
cash
restricted
cash
prepaid
expenses
assets
current
total
current
assets
assets
property
equipment
net
right
use
assets
net
deposits
prepaid
expenses
assets
deferred
tax
asset
intangible
assets
net
total
assets
liabilities
shareholders
equity
current
liabilities
accounts
payable
accrued
expenses
liabilities
lease
liabilities
total
current
liabilities
liabilities
lease
liabilities
total
liabilities
shareholders
equity
ordinary
shares
par
value
shares
authorized
september
december
shares
issued
outstanding
september
december
respectively
deferred
shares
par
value
shares
authorized
issued
outstanding
september
december
deferred
b
shares
par
value
shares
authorized
issued
outstanding
september
december
deferred
c
shares
par
value
share
authorized
issued
outstanding
september
december
additional
capital
accumulated
comprehensive
loss
accumulated
deficit
total
shareholders
equity
total
liabilities
shareholders
equity
